Cargando…
No neurodevelopmental benefit of cerebral oximetry in the first randomised trial (SafeBoosC II) in preterm infants during the first days of life
AIM: Cerebral hypoxia has been associated with neurodevelopmental impairment. We studied whether reducing cerebral hypoxia in extremely preterm infants during the first 72 hours of life affected neurological outcomes at two years of corrected age. METHODS: In 2012‐2013, the phase II randomised Safeg...
Autores principales: | Plomgaard, Anne M., Alderliesten, Thomas, van Bel, Frank, Benders, Manon, Claris, Olivier, Cordeiro, Malaika, Dempsey, Eugene, Fumagalli, Monica, Gluud, Christian, Hyttel‐Sorensen, Simon, Lemmers, Petra, Pellicer, Adelina, Pichler, Gerhard, Greisen, Gorm |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6585779/ https://www.ncbi.nlm.nih.gov/pubmed/29908039 http://dx.doi.org/10.1111/apa.14463 |
Ejemplares similares
-
Early biomarkers of brain injury and cerebral hypo- and hyperoxia in the SafeBoosC II trial
por: Plomgaard, Anne M., et al.
Publicado: (2017) -
Brain injury in the international multicenter randomized SafeBoosC phase II feasibility trial: cranial ultrasound and magnetic resonance imaging assessments
por: Plomgaard, Anne M, et al.
Publicado: (2016) -
The SafeBoosC II randomized trial: treatment guided by near-infrared spectroscopy reduces cerebral hypoxia without changing early biomarkers of brain injury
por: Plomgaard, Anne M., et al.
Publicado: (2016) -
The SafeBoosC phase II clinical trial: an analysis of the interventions related with the oximeter readings
por: Riera, Joan, et al.
Publicado: (2016) -
Early cerebral hypoxia in extremely preterm infants and neurodevelopmental impairment at 2 year of age: A post hoc analysis of the SafeBoosC II trial
por: Plomgaard, Anne Mette, et al.
Publicado: (2022)